PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2012
CASE
AUTH/2491/3/12 Roche Products

AUTH/2491/3/12: Member of the public v Roche β€” Conduct of a clinical trial (out of scope; no breach)

PMCPA case AUTH/2491/3/12 (Member of the public v Roche) about conduct of a clinical trial. The matter was ruled outside the scope…

2015
CASE
Sanofi

Sanofi Toujeo leavepiece: BRIGHT study titration-phase hypoglycaemia data given disproportionate emphasis

A Toujeo promotional leavepiece highlighted favourable 0–12 week hypoglycaemia results vs degludec with prominent graphics, while 24‑week comparable outcomes were downplayed. PMCPA…

2016
CASE
AUTH/2894/11/16 Mitsubishi Tanabe

AUTH/2894/11/16: Director v Mitsubishi Tanabe β€” Clinical trial disclosure (BindRen) (No breach / Outwith scope)

PMCPA case AUTH/2894/11/16 (Director v Mitsubishi Tanabe) concerning clinical trial disclosure for BindRen. The case outcome was no breach and it was…

2019
CASE
AUTH/3244/9/19 Leo Pharma ⭐ Case of the Week

Leo Pharma: MSL activity deemed promotional, triggering ABPI exam requirement (AUTH/3244/9/19)

Anonymous employee complaint about Leo’s dermatology MSLs. Panel found some MSL speaker-meeting activity was promotional, so MSLs should have taken an appropriate…

2020
CASE
AUTH/3329/3/20 Boehringer Ingelheim

Boehringer Ingelheim: Pradaxa website landing page alleged public promotion (AUTH/3329/3/20) – No breach

Complaint alleged Pradaxa.co.uk encouraged the public to seek more info about a POM. Panel found the public-facing section was factual reference material,…

2020
CASE
AUTH/3319/3/20 AstraZeneca

AstraZeneca: Symbicort COPD formulary guide prescribing information challenged as out of date (AUTH/3319/3/20)

A UK health professional alleged Symbicort COPD formulary material omitted a newer SPC warning. PMCPA found the warning related to asthma, not…

2019
CASE
AUTH/3228/7/19 Ipsen

Merz v Ipsen: Dysport β€˜long-lasting effect’ campaign found misleading on appeal (AUTH/3228/7/19)

After inter-company dialogue, Ipsen’s Dysport messaging implying superior duration of effect was found misleading and not supportive of rational use. Appeal Board…

2019
CASE
Novartis Pharmaceuticals UK

Novartis heart failure therapy review service: complaint about third-party email implying β€˜client product/therapy priorities’ (No breach)

Anonymous group alleged a third-party email showed commercial bias in Novartis-sponsored heart failure therapy reviews. Panel and Appeal Board had concerns about…

2020
CASE
AUTH/3363/6/20 GlaxoSmithKline ⭐ Case of the Week

AUTH/3363/6/20: GSK Anoro Ellipta public website page – no breach (reference information and certification upheld)

A UK health professional alleged GSK’s public Anoro Ellipta webpage promoted a POM and encouraged requests for treatment, and questioned certification/expiry. The…

2020
CASE
AUTH/3390/9/20 Janssen

Janssen: UK employee’s LinkedIn post about unlicensed Covid-19 vaccine candidate ruled pre-authorisation promotion (AUTH/3390/9/20)

A Janssen UK employee reposted/commented on a US exec’s LinkedIn update about a Covid-19 vaccine candidate entering Phase 3. Panel ruled pre-authorisation…

2019
CASE
Britannia

Britannia advisory boards for Apo-Go: poor governance and record-keeping led to Clause 9.1 and 23.1 breaches

Ex-employee alleged Apo-Go advisory boards were promotional. Panel found high standards breach (9.1). On appeal, poor documentation, SOP deviations and missing minutes…

2019
CASE
Pfizer

Pfizer: Senior employee’s LinkedIn post linking to BBC β€˜vaccine judged safe’ headline breached ABPI Code

A senior Pfizer UK employee posted a proud LinkedIn message linking to a BBC article with an unqualified β€œsafe” headline about the…

2021
CASE
AUTH/3468/2/21 Sanofi

Sanofi breached ABPI Code after uncertified internal email to salesforce about Toujeo patient materials and digital campaigns (AUTH/3468/2/21)

An internal salesforce email mixing patient booklet availability with digital campaign screenshots wasn’t itself improper, but it was treated as rep briefing/instructions…

2020
CASE
AUTH/3414/11/20 Novartis Pharmaceuticals UK ⭐ Case of the Week

Novartis: corporate webpage pipeline table ruled to promote POMs to the public and an unlicensed medicine (AUTH/3414/11/20)

Novartis’ corporate webpage listed pipeline products with indications and trial details. PMCPA ruled it promoted two licensed POMs to the public and…

2021
CASE
AUTH/3465/2/21 Vifor Pharma

AUTH/3465/2/21: Complainant v Vifor β€” Venofer symposium and alleged off-licence promotion (No breach)

Anonymous UK health professional alleged a Vifor-sponsored PIVOTAL sub-analysis symposium promoted off-licence Venofer use. Panel found PIVOTAL dosing aligned with clinically accepted…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training